A study on GSK’s R&D in China
Group 2
Viktor Bertilsson 胡沈泓 简铃晏 孙 丹 王凯婕 尹昭晶 张祺昀 Yu Helene – 11349086012 – 10300690059 – 11307100503 –09300240079 – 10300690072 – 11340116024 – 11300300027 – 11340686007
1
TABLE OF CONTENTS
INTRODUCTION ............................................................................................................................ 4 METHODOLOGY ........................................................................................................................... 4 BACKGROUND .............................................................................................................................. 4 GSK in China ............................................................................................................................ 4 GSK’s R&D in China................................................................................................................ 5 The Unique R&D Process ......................................................................................................... 5 Introduction of DPUs ............................................................................................................ 5 Pharmaceuticals R&D ........................................................................................................... 6 Vaccines R&D ....................................................................................................................... 6 ANALYSIS ON GSK’S R&D IN CHINA........................................................................................ 6 1 Motives to enter China ........................................................................................................... 6 1.1 Untapped huge market gap.............................................................................................. 6 1.2 Legal and policy support ................................................................................................. 7 2 R&D Development in China...